{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"15.360","floor":"15.360"},"ipodate":{"start":"2020-05-05 00:00:00","end":"2020-05-08 00:00:00"},"minimumcapital":"15514.78","subscribed":"1184.41","marketcap":"93.70億","H_marketcap":"--","pe":"--","codesrate":"8.50","link":"https://staticpdf.iqdii.com/stockdata/notice/09996/2020/2020050500012_c.pdf","ipopricing":"15.360","resultdate":"2020-05-14 00:00:00","enddate":"2020-05-08 00:00:00","listeddate":"2020-05-15 00:00:00","issuenumber":"15251.10萬","issuenumberhK":"7625.60萬","issuenumberother":"7625.50萬","grayprice":"25.30","sponsors":"摩根士丹利亞洲有限公司,華泰金融控股(香港)有限公司","raisemoney":"220030.00萬","use":"1、約65.0%（或1,430.2百萬港元），將撥作開發及商業化我們的核心產品TaurusOne?以及其他主要在研產品；\n2、約10.0%（或220.0百萬港元），將用于我們管線中的其他在研產品的正在進行的臨床前研究及擬訂的臨床試驗、準備注冊備案及潛在商業化推出；\n3、約8.0%（或176.0百萬港元），將用于加強我們的研發能力以豐富我們的產品管線，其主要包括為我們的內部研發團隊招聘及支付三年薪金予高素質人才，尤其是具有豐富設計及開發技能及經驗的工程師；\n4、約10.0%（或220.0百萬港元），將用于通過潛在戰略收購、投資、合作伙伴及許可機會以擴大我們的產品組合或知識產權組合；\n5、約7.0%（或154.1百萬港元），將用作營運資金及其他一般企業用途。","shares":1000,"leadagent":"摩根士丹利亞洲有限公司,華泰金融控股(香港)有限公司,中銀國際亞洲有限公司,瑞士銀行香港分行,招銀國際融資有限公司,國泰君安證券(香港)有限公司","bookrunners":"摩根士丹利亞洲有限公司,華泰金融控股(香港)有限公司,中銀國際亞洲有限公司,瑞士銀行香港分行,招銀國際融資有限公司,國泰君安證券(香港)有限公司","coordinator":"摩根士丹利亞洲有限公司,華泰金融控股(香港)有限公司,中銀國際亞洲有限公司,瑞士銀行香港分行","firstDayOpen":"26.80","IsEiio":0,"Interestdays":6,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"摩根士丹利亞洲有限公司","code":"E09996","name":"沛嘉醫療－Ｂ","fullname":"沛嘉醫療有限公司"},"institutioninfo":{"principaloffice":"中國江蘇省蘇州市蘇州工業園區中田巷8號","registrars":"香港中央證券登記有限公司","registrarstel":"(852) 2862 8628","chairman":"張一","secretary":"孫佩真","telephone":"(852) 3150 6788","substantialshareholders":"張一、張葉萍及葉紅(23.68%),LAV(10.23%),Matrix Partners(7.38%)","principalactivities":"公司專注于中國高增長的介入手術醫療器械市場，且為中國各經導管瓣膜治療醫療器械市場及神經介入手術醫療器械市場中具領先地位的國內參與者。","website":"www.peijiamedical.com"},"managerinfo":[{"managername":"張一","post":"首席執行官兼董事長","rankno":1},{"managername":"張葉萍","post":"執行董事","rankno":2},{"managername":"葉紅","post":"執行董事","rankno":3}],"investorinfo":[{"institutionname":"Fidelity International","shareholding":"25,231,000.0","percentage":16.54,"ReleaseDate":"2020-11-15 00:00:00","relatedparty":"富達基金(香港)有限公司","subsidiary":["Fidelity International"],"InverstorType":"基金"},{"institutionname":"中國國有企業結構調整基金股份有限公司","shareholding":"10,092,000.0","percentage":6.62,"ReleaseDate":"2020-11-15 00:00:00","relatedparty":"國務院國資委","subsidiary":["中國誠通控股集團有限公司","中國國有企業結構調整基金股份有限公司","中國機械工業集團有限公司","中國商用飛機有限責任公司","中國西電集團公司"],"InverstorType":"公司"},{"institutionname":"Prime Capital Funds","shareholding":"6,560,000.0","percentage":4.3,"ReleaseDate":"2020-11-15 00:00:00","relatedparty":"涌金資產管理有限公司","subsidiary":["Prime Capital Funds","Dragon Billion China Master Fund"],"InverstorType":"基金"},{"institutionname":"Hudson Bay Master Fund LTD","shareholding":"5,046,000.0","percentage":3.31,"ReleaseDate":"2020-11-15 00:00:00","relatedparty":"Hudson Bay Capital Management LP","subsidiary":["HBC Asia Healthcare Opportunities V LLC","Hudson Bay Master Fund LTD","HBC Asia Healthcare Opportunities VII LLC"],"InverstorType":"基金"}],"TotalShareholdingPercentage":49.96},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":7}